Cargando…
Complete response to immunotherapy combined with an antiangiogenic agent in multiple hepatic metastases after radical surgery for advanced gallbladder cancer: a case report
Most advanced gallbladder cancers (GBCa) are unresectable or metastatic once diagnosed, and even patients who undergo surgery have a high risk of recurrence and metastasis. Immunotherapy, especially immune checkpoint inhibitors (ICIs), combined with an antiangiogenic agent, is an emerging prospectiv...
Autores principales: | Rao, Jianhua, Xia, Jinguo, Yang, Wenjie, Wu, Chen, Sha, Bowen, Zheng, Qitong, Cheng, Feng, Lu, Ling |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7791255/ https://www.ncbi.nlm.nih.gov/pubmed/33437808 http://dx.doi.org/10.21037/atm-20-4420 |
Ejemplares similares
-
Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy
por: Pang, Lan-Lan, et al.
Publicado: (2023) -
Analysis of the efficacy and prognostic factors of PD-1 inhibitors in advanced gallbladder cancer
por: Zheng, Qitong, et al.
Publicado: (2021) -
Interaction between Immunotherapy and Antiangiogenic Therapy for Cancer
por: Furukawa, Koichi, et al.
Publicado: (2020) -
Immunotherapy combined with antiangiogenic agents in patients with advanced malignant pleural mesothelioma: A case report
por: Xuan, Tian-Tian, et al.
Publicado: (2022) -
Angiogenesis and antiangiogenic agents in cervical cancer
por: Tomao, Federica, et al.
Publicado: (2014)